Fig. 11

Flow cytometric analysis of MMP in human CRC cell lines treated with Sora, Cur, and a combination of both. A The SW1116 human CRC cell line was UT, or treated with Sora (5 µM), Cur (200 µM), Cur (400 µM), and simultaneous combinations of Sora (5 µM) and Cur (200 or 400 µM) for 72 h. B The SW837 human CRC cell line was UT, or treated with Sora (5 µM), Cur (200 µM), Cur (400 µM), and sequential treatments of Sora (5 µM) and Cur (200 or 400 µM) for 72 h. The red and white curves are the control and experimental groups, respectively. MMP, mitochondrial membrane potential; Sora, sorafenib; Cur, curcumin; UT, untreated; CRC, colorectal cancer